During in vitro decidualization of human endometrial stromal cells (HESCs), medroxyprogesterone acetate (MPA) inhibits expression of the potent extracellular matrix (ECM)-degrading protease stromelysin-1 (MMP-3), but enhances PRL expression. Consistent with its priming role in vivo, estradiol (E 2 ) augments these effects. In the current study, immunoblot analysis revealed that coincubation with 10 Ϫ6 M RU 486 blocked the inhibition in HESC-secreted MMP-3 levels (50,000 mol wt) evoked by 10
greater increases seen in RU 486-containing medium (10-fold protein, 100-fold messenger RNA). Previously, we showed that RU 486 upregulated E 2 ϩ MPA-inhibited plasminogen activator expression in the cultured HESCs. Extrapolation of these in vitro observations to endometrial events following RU 486 administration suggests that coordinate enhancement of MMP-3 and plasminogen activator expression promotes proteolysis of the stromal/decidual ECM, which leads to endometrial sloughing. Moreover, destabilization of endometrial microvessels resulting from degradation of their surrounding ECM is consistent with the heavy menstrual bleeding stemming from RU 486 administration. However, in contrast to the marked RU 486-initiated reversal of MMP-3 expression, RU 486 did not significantly reverse E 2 ϩ MPA-enhanced PRL secretion by the cultured HESCs. Interestingly, decidual PRL, unlike decidual MMP-3, does not appear to play a role in menstruation. Interleukin-1␤ counteracted E2 ϩ MPA-mediated inhibition of secreted MMP-3 levels, implying that leukocyte/trophoblast-derived cytokines can modulate steroid-regulated MMP-3 expression by stromal/decidual cells during menstruation and pregnancy. (J Clin Endocrinol Metab 82: 188 -193, 1997) I N WOMEN, progesterone acts on the estradiol (E 2 )-primed endometrium to initiate the transformation of stromal cells to decidual cells around the spiral arterioles. Under continued steroid stimulation, this process of decidualization (DZ) spreads wave-like to establish the decidual cell as a major cell type of the luteal phase and pregnant endometrium (1) . Conversion of the interstitial extracellular matrix (ECM) of the proliferative endometrium to a decidual ECM enriched in basement membrane-like components is integral to the DZ process (2) . This transformation requires synthesis of new ECM proteins, but is greatly aided by the simultaneous inhibition of proteases that degrade these proteins.
Progestin-modulated DZ of cultured human endometrial stromal cells (HESCs) involves changes that reduce ECMdegrading potential. Accordingly, there is coordinate inhibition in the expression of the matrix metalloproteinase (MMP) stromelysin-1 (MMP-3) (3, 4), which degrades several ECM components and can activate other MMP zymogens (5), with the plasminogen activators (PAs) (6, 7) , which interact with the MMPs to carry out efficient proteolysis of ECM components (5, 8) . Conversely, expression of the potent PA inhibitor-1 (PAI-1) is elevated (7, 9, 10) . Consistent with the differential actions of ovarian steroids in vivo whereby E 2 priming elevates human endometrial progesterone receptor levels (11), E 2 is ineffective alone, but augments the progestin-mediated effects in the HESCs on the expression of MMP-3 (3), the PAs (7), and PAI-1 (7, 10) .
Recent work suggested that a model based on in vitro decidualized stromal cells (12) was well-suited to study menstruation-related changes elicited by a decline in circulating ovarian steroids. Thus, after HESCs were incubated with E 2 ϩ progestin, the antiprogestin RU 486 (mifepristone) markedly reversed the expression of progestin-enhanced tissue factor (13) and PAI-1 (14) and progestin-inhibited PAs (14) . The purpose of the current study was to further explore the utility of cultured HESCs as a menstruation model by comparing steroid withdrawal effects of RU 486 on secreted levels of MMP-3 and PRL. Degradation of the endometrial ECM as mediated by MMP-3 is expected to elicit menstruation-associated sloughing of the functional layer. Moreover, specific targeting by MMP-3 of the endometrial microvasculature ECM should enhance capillary fragility and promote bleeding. These processes are relevant to the clinical administration of RU 486, which leads to endometrial ECM degradation and hemorrhage (15, 16) . By contrast, endometrial PRL is a classical DZ marker that does not appear to play a role in menstruation (17) . Because endometrial-derived MMP-3 and PRL differ in their relationship to menstruation, which is initiated in response to withdrawal of circulating ovarian steroids, we hypothesize that differential expression of these endpoints will result from removal of such steroids from cultured HESCs.
Materials and Methods

Tissues and stromal cell isolation
After obtaining informed consent, specimens of predecidualized cycling endometria from follicular and luteal phases were derived from patients undergoing hysterectomy for myomas and were transported to a sterile laminar flow hood. A small portion was formalin-fixed for future dating by the histological criteria of Noyes et al. (18) . The remainder of each specimen was trimmed and minced in MEM containing 1% of an antibiotic-antimycotic mixture (GIBCO, Grand Island, NY), then digested for 1.5 h at 38 C with type I collagenase (Worthington Biochemical Corp., Freehold, NJ) in basal medium (BM) [a phenol redfree 1:1 vol/vol mix of DMEM (Gibco, Grand Island, NY) and Ham's F-12 (Flow Laboratories, Rockville, MD), with 100 U/mL penicillin, 100 g/mL streptomycin, 0.25 g/mL fungizone] supplemented with 10% charcoal-stripped calf serum (10% SCS). Stromal cells were isolated from the endometrial digestate as previously described (19) .
Experimental culture conditions
Parallel cultures of stromal cells were grown to confluence (3-4 ϫ 10 4 cells/cm 2 ) in a 37 C, 95% air:5% CO 2 incubator in BM ϩ 10% SCS, renewing the medium every 4 days.
Steroid specificity
The experimental period was initiated in fresh BM ϩ 10% SCS containing either vehicle control (0.1% ethanol), E 2 , medroxyprogesterone acetate (MPA), dexamethasone (Dex), E 2 ϩ MPA, E 2 ϩ Dex, E 2 ϩ MPA ϩ RU 486, or E 2 ϩ Dex ϩ RU 486. After 5 days in the incubator, the conditioned medium was collected and centrifuged, and the supernatants stored at Ϫ70 C for MMP-3 and PRL analysis (see below). The cells of one set of dishes were harvested by scraping with a rubber spatula, then pelleted by centrifugation and frozen for later analysis of DNA and protein content. Fresh corresponding medium was added to the remaining two sets of cultures. These were returned to the incubator, and the procedure repeated for additional 5-day intervals.
RU 486 reversal studies
Using the 37 C incubator, confluent stromal cell cultures were exposed to BM ϩ 10% SCS with 10 Ϫ8 mol/L E 2 and 10 Ϫ7 mol/L MPA, replacing the medium every 3-4 days. After 10 days, the cultures were washed twice with BM ϩ 10% SCS, and steroid withdrawal was routinely carried out for 4 days in BM ϩ 10% SCS containing either vehicle control or 10 Ϫ6 m RU 486, while parallel cultures were maintained in 10 Ϫ8 mol/L E 2 ϩ 10 Ϫ7 mol/L MPA. In some experiments this steroid withdrawal paradigm was carried out for additional 4-and 8-day intervals, whereas in one experiment onapristone (Schering, Berlin, Germany) was substituted for RU 486. The experiments were terminated as described above by collecting the conditioned medium for MMP-3 and PRL determinations and harvesting the cells.
Immunoblot analysis for the presence of MMP-3
Cell-conditioned medium was mixed with Laemmli sample buffer containing 5% 2-mercaptoethanol, subjected to 7% PAGE, then electrotransferred onto nitrocellulose. After blocking nonspecific sites with 5% powdered low fat milk, the blots were incubated with a specific anti-MMP-3 rabbit polyclonal antibody, generously supplied by Dr. M. Lark (Merck Research Laboratories, Rahway, NJ). The blots were then washed and exposed to [ 125 I] protein-A (200,000 cpm/ml) for 30 min. After repeat washing and autoradiography, the effects of the various treatments on relative levels of MMP-3 were assessed by densitometry.
PRL assay
The stromal cell culture-derived conditioned media were thawed and assayed for immunoreactive PRL using a double antibody kit according to the manufacturer's specifications (Amersham, Arlington Heights, IL).
Protein and DNA assay
The protein content of the cell pellets was determined using a modified Bradford assay (Bio-Rad Labs., Hercules, CA). The total DNA content was determined as previously described (3).
Northern analysis for the presence of MMP-3 messenger RNA (mRNA)
Total RNA was extracted from cultured stromal cells by a guanidinium thiocyanate-chloroform method (RNAzol-B, Cinna Biotecx Laboratories, Houston, TX). Approximately 25 g total RNA from each of the experimental cultures and molecular weight RNA standards (Boehringer-Mannheim, Indianapolis, IN) were separated on a 1% agarose gel containing 2.2 mol/L formaldehyde, then transferred to a nylon membrane. Levels of MMP-3 mRNA were detected with a probe generously supplied by Dr. N. Hutchinson (Merck Research Laboratories), which was labeled with [
32 P]deoxy-cytidine 5Ј-triphosphate to high specific activity by random priming with a Boehringer-Mannheim kit. Hybridization was performed by standard methods, as previously described (13) , and the washed filters were exposed to Kodak XAR film (Eastman Kodak, Rochester, NY). Signals were evaluated by densitometric scanning of autoradiograms. To standardize total RNA loads, the membranes were stripped and reprobed with a 32 P-labeled glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe as described previously (13) .
Results
Specificity of progestin-inhibited MMP-3 expression
The immunoblot depicted in Fig. 1 reveals that E 2 ϩ MPAelicited inhibition of stromal cell-secreted MMP-3 is progestin regulated. Thus, although MPA is a weak glucocorticoid, the strong glucocorticoid Dex failed to affect secreted MMP-3 levels whether added alone, or in sharp contrast to the results 
for MPA, with E 2 . Moreover, the antiprogestin RU 486, which can act as an antiglucorticoid at high concentrations (16) , counteracted most of the E 2 ϩ MPA-inhibited MMP-3 output, indicating that RU 486 is an antiprogestin in the HESCs. The apparent lack of inhibitory response to MPA alone in this cell preparation reflects the need for coadministered estrogen to maintain adequate progesterone receptor levels (11, 20) .
Reversal of progestin-inhibited MMP-3 mRNA expression
Parallel HESC cultures were incubated with 10 Ϫ8 mol/L E 2 ϩ 10 Ϫ7 mol/L MPA, then either continued in E 2 ϩ MPA or E 2 alone, or subjected to steroid withdrawal in medium containing 0.1% ethanol (vehicle control) or 10 Ϫ6 mol/L RU 486. Figure 2 displays steady state MMP-3 mRNA levels for the withdrawal intervals of 0 -4 and 8 -12 days. After 0 -4 days, a faint 2.1-kilobase band corresponding to MMP-3 mRNA (3, 21) was detected in HESCs maintained in E 2 ϩ MPA. Its levels were enhanced by the change to control medium and markedly enhanced in medium containing RU 486. At the end of the 8-to 12-day interval, continuous exposure to E 2 ϩ MPA had virtually eliminated the appearance of MMP-3 mRNA. Consistent with removal of residual progestin from the culture medium, up-regulation of MMP-3 mRNA levels elicited by withdrawal to control medium was now equivalent to that produced by RU 486. As expected from the progesterone receptor-augmenting action of E 2 , the switch to E 2 alone was almost as effective as E 2 ϩ MPA in suppressing MMP-3 levels over the initial 0-to 4-day withdrawal interval. However, somewhat less inhibition was seen as residual progestin was removed by 8 -12 days. Densitometric evaluation of the effects of 0 -4 days of steroid withdrawal on MMP-3 mRNA levels in cultured HESCs derived from three endometrial specimens (Fig. 3) shows that RU 486 was about 10-fold more effective than withdrawal to control medium in reversing E 2 ϩ MPA-elicited inhibition. Although the results shown in Figs. 2 and 3 were obtained with 10-fold excess RU 486 compared with MPA, RU 486 added at twice the MPA concentration in one experiment also effectively reversed the E 2 ϩ MPA-elicited inhibition (results not shown).
Reversal of progestin-inhibited MMP-3 protein expression
After confluent HESC cultures were incubated with E 2 ϩ MPA for 10 days, immunoblot analysis was used to measure MMP-3 levels in the medium of parallel cultures maintained in E 2 ϩ MPA or subjected to steroid withdrawal. Consistent with steroid withdrawal-elicited increases in MMP-3 mRNA levels (Figs. 2 and 3) , the autoradiogram of Fig. 4 indicates that compared with cultures maintained in E 2 ϩ MPA, se-
FIG. 2. Northern analysis of steroid withdrawal effects on MMP-3 mRNA levels by HESCs. Monolayers were incubated in 10
Ϫ8 mol/L E 2 ϩ 10 Ϫ7 mol/L MPA for 10 days to suppress MMP-3 expression, and then grouped according to treatments:
mol/L MPA; B ϭ E 2 ; C ϭ control medium; D ϭ 10 Ϫ6 mol/L RU 486; I ϭ 0 -4 days of steroid withdrawal; II ϭ 8 -12 days of steroid withdrawal. MMP-3, levels of 2.1-kb MMP-3 mRNA; GAPDH, levels of GAPDH mRNA (a housekeeping gene unaffected by steroids to normalize for differences in total RNA loads). FIG. 3 . RU 486 reversal of progestin-suppressed endometrial stromal cell MMP-3 mRNA expression. Levels of MMP-3 mRNA extracted from cultured HESCs were assessed by Northern analysis and densitometry; the ordinate displays results as ratio of intensities for mRNAs for MMP-3 to GAPDH to normalize for differences in RNA loading. After 10 days of incubation in 10 Ϫ8 mol/L E 2 ϩ 10 Ϫ7 mol/L MPA (E ϩ P), parallel cultures were incubated for 4 days in C ϭ control medium; E ϩ P ϭ 10 Ϫ8 mol/L E 2 ϩ 10 Ϫ7 mol/L MPA; RU ϭ 10 Ϫ6 mol/L RU 486. Shown are mean Ϯ SEM for confluent monolayers from three specimens, with results normalized to withdrawal to RU 486 set at 100%. By Student's t test: *, RU vs. control; P Ͻ 0.05. **, RU vs. E ϩ P; P Ͻ 0.05.
FIG. 4. Immunoblot analysis of steroid withdrawal effects on secreted MMP-3 by cultured human endometrial stromal cells. Monolayer cultures were incubated in 10
Ϫ8 mol/L E 2 ϩ 10 Ϫ7 mol/L MPA for 10 days to suppress MMP-3 expression and then distributed among four groups: A ϭ control medium; B ϭ 10 Ϫ8 mol/L E 2 ϩ 10 Ϫ7 mol/L MPA; C ϭ 10 Ϫ6 M RU 486; D ϭ E 2 ϩ MPA ϩ RU 486. Group I ϭ 0 -4 days of steroid withdrawal; Group II ϭ 4 -8 days of steroid withdrawal. Lanes were loaded with medium normalized to protein content of harvested cells.
creted MMP-3 protein levels increased significantly after 0 -4 days of steroid withdrawal to control medium, with much greater enhancement resulting when RU 486 was added alone or together with E 2 ϩ MPA. After 4 -8 days, the withdrawal effects of control medium began to approach those of RU 486 in enhancing secreted MMP-3 levels. Onapristone, an antiprogestin with fewer antiglucorticoid effects than RU 486 (22) , was found to be equivalent to an equimolar concentration of RU 486 in reversing E 2 ϩ MPA-mediated inhibition of secreted MMP-3 levels in the one stromal cell preparation studied (results not shown).
Reversal of MMP-3 and PRL expression
Cultured stromal cells derived from seven endometrial specimens were incubated for 10 days with E 2 ϩ MPA followed by 4 days of steroid withdrawal. Figure 5 compares MMP-3 levels measured by immunoblot analysis, and PRL measured by RIA, in aliquots of the HESC-conditioned medium during the withdrawal period. RU 486 markedly reversed E 2 ϩ MPA-inhibited effects on MMP-3 output in each of the seven stromal cell preparations (range, 5 to 75-fold) resulting in a statistically significant mean increase in secreted MMP-3 levels of about 10-fold (P Ͻ 0.009). HESCsecreted PRL levels are reported to be essentially undetectable under basal conditions, but are readily detectable in response to progestins, and further enhanced by E 2 ϩ progestins (23, 24) . Despite this progestin dependence, and unlike the effects on secreted MMP-3 levels, RU 486 did not exert consistent effects on PRL output among the seven experiments. Accordingly, the averaged results show no significant differences in PRL levels in parallel cultures maintained in E 2 ϩ MPA or withdrawn to either control or RU 486-containing medium. Figure 6 shows immunoblot analysis for the presence of MMP-3 in HESC-conditioned medium during incubation in a defined medium (DM) [described in (3)] containing either vehicle (control), E2, MPA, E2 ϩ MPA, interleukin-1␤ (IL-1␤), or steroids ϩ IL-1␤. In the incubations with steroids alone, MPA, but not E2, reduced secreted levels of MMP-3 (50,000 mw), whereas, augmented inhibition occurred in response to E2 ϩ MPA. By contrast, IL-1␤ markedly elevated MMP-3 levels whether added alone or with the steroids. The stimulatory effects of IL-1␤ not only counteracted E2 ϩ MPAelicited inhibition of secreted MMP-3 levels, but produced a further increase above control levels.
Steroid-cytokine effects on MMP-3 expression
Discussion
The PAs, which can mediate the breakdown of matrices undergoing rapid turnover, interact with the MMPs, which can degrade the more slowly remodeled scaffolding structures that comprise the bulk of the ECM (5, 8) , to regulate ECM turnover. Among the MMP family, MMP-3 utilizes an unusually wide range of ECM substrates, including proteoglycan core protein, type IV and V collagen, and the nonhelical amino-and carboxyl-terminal peptides of type II collagen, fibronectin, and laminin (5). Consequently, MMP-3 is uniquely capable of controlling degradation of interstitialtype ECM components surrounding precursor endometrial stromal cells as well as peridecidual cell basement membrane-type components. Moreover, MMP-3 can activate zy- Ϫ8 mol/L E2 (E), 10 Ϫ7 mol/L MPA (P), E2 (E) ϩ MPA (P), 2 U/mL IL-1␤, or steroids ϩ IL-1␤. The conditioned medium was collected at 3-day intervals, and the supernatants were stored at Ϫ70 C. The lanes were loaded with medium normalized to the protein content of cells harvested after 3-6 days of experimental incubation. mogenic forms of other MMPs such as interstitial collagenase and the 92-kilodalton gelatinase type IV collagenase (25, 26) . In nonfertile human menstrual cycles, declining circulating ovarian steroid levels trigger protease-mediated degradation of the endometrial ECM, leading to shrinkage of the stromal compartment, then sloughing and expulsion of the functional endometrial layer in the menstrual fluid (27) . A consequence of their widespread distribution in the premenstrual endometrium and high concentration at specific perivascular sites is that decidual cells are well situated to regulate menstrual events. In situ hybridization of human endometrial sections provided evidence to support such a role for decidual cell-derived MMP-3. Thus, MMP-3 mRNA was localized to the stroma of human premenstrual endometrium where its levels were in low abundance during the progesterone-dominated luteal phase, but increased concomitant with estrogen and progesterone withdrawal leading to menstruation (28) .
Results presented in this study complement those of other reports to suggest a mechanism by which the actions of RU 486-elicited steroid withdrawal effects on the decidualized HESCs to promote endometrial ECM degradation and bleeding of menstruation. Thus, synergism of RU 486-enhanced MMP-3 activity with RU 486-increased PA activity in decidualized stromal cells (14) would accelerate endometrial sloughing. Moreover, MMP-3-mediated degradation of the perivascular ECM would compromise the structural integrity of endometrial microvessels. Predictably, the resultant increase in capillary fragility would exacerbate bleeding initiated by both tPA, the primary mediator of fibrinolysis (8), as well as the procoagulant tissue factor, the primary mediator of hemostasis via fibrin generation (29) . Thus, expression of tissue type PA (tPA) is enhanced (14) , and that of tissue factor is inhibited (13) in in vitro decidualized HESCs subjected to RU 486-elicited steroid withdrawal.
RU 486 is an effective abortifacient when administered within 50 postmenstrual days (30) , and a contragestive within 72 h of intercourse (31) . Because RU 486 interferes with implantation in rodents (32) , it could play a similar role in primates. However, the marked endometrial ECM degradation and bleeding that accompany RU 486 use (16) emphasize the utility of in vitro D2 for evaluating clinical aspects of RU 486 use. That use of this model should be extended to measurements of the potent vasoconstrictor endothelin-1, and its inactivator enkephalinase, as suggested by the work of Casey et al. (33) . They reported that during the perimenstrual period, the expression of endothelin-1 is increased, whereas that of enkephalinase is inhibited (33) . These changes are consistent with the marked vasoconstriction and resulting hypoxia that precedes menstruation.
In contrast to the profound up-regulation in secreted MMP-3 levels triggered by 4 days of RU 486-induced steroid withdrawal, Fig. 5 indicates that parallel aliquots of conditioned medium from HESCs maintained in E 2 ϩ MPA or withdrawn to RU 486 contained similar PRL levels. In human endometrium, decidual cell-derived PRL (34) is proposed to play diverse roles in pregnancy including: 1) osmoregulation of the amniotic fluid (35, 36) ; 2) modulation of prostaglandin E synthesis in the human amniochorion (35); and 3) immunoregulation during implantation (17) . Although PRL exerts vascular effects in rats, the absence of PRL receptors in human endometrial vasculature argue against the latter as PRL targets. Furthermore, a survey of the literature turned up no evidence supporting a role for endometrial PRL in menstruation (17) . Previously, Tseng et al. (37) noted that after PRL expression in HESC monolayers had been progestin-enhanced, RU 486-elicited steroid withdrawal superinduced the transcription rate as well as steady state levels of PRL mRNA. Paradoxical superinduction was similarly observed for insulin-like growth factor binding protein-1 (37) , which mediates embryo-endometrial interactions (38) , but does not appear to play a role in menstruation.
Steroid responsiveness therefore appears to define two categories of DZ-related markers in HESC cultures. One category includes proteins such as tissue factor, the PAs, PAI-1, and MMP-3. Steroids initiate a change in their expression, and this altered expression is tightly coupled to continued steroid exposure. These proteins are therefore highly sensitive to steroid withdrawal and are postulated to play key roles in menstruation. However, they may also be involved in maintaining hemostasis and in regulating ECM degradation during trophoblast invasion. A second category includes PRL and insulin-like growth factor binding protein-1. Changes in their expression are also steroid initiated. However, continued altered expression is likely regulated by paracrine effectors from trophoblast and placenta. These proteins are postulated to mediate decidual-trophoblast interactions. A recent report showed that several cytokines modulated integrin expression in the cultured HESCs, whereas the cells were refractory to ovarian steroids (39) . This may signal the existence of a third category of marker, whose expression by stromal/decidual cells depends solely on paracrine effectors derived from leukocytes, trophoblast, and/or placenta. Interleukin and tumor necrosis factor were recently shown to upregulate the expression of several MMPs, including MMP-3, in the cultured HESCs (40) . The observation reported in the current study that IL-1␤ abolished E2 ϩ MPA-mediated inhibition of MMP-3 expression in the cultured HESCs suggests that steroid-cytokine interactions are involved in the DZ reaction. Identifying cytokine effectors derived from endometrial cells, leukocytes, trophoblast, and/or placental cells, which act as autocrine/paracrine mediators that induce or inhibit the DZ reaction offers a challenging question for reproductive biologists.
